Please login to the form below
rare autoimmune disease
This page shows the latest rare autoimmune disease news and features for those working in and with pharma, biotech and healthcare.
GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
The rare autoimmune disease affects two to ten people per million and has limited treatments. ... Affecting two to ten people per million, SSc is a rare autoimmune disease that causes unusual growth of connective tissues and can affect a patient’s
Latest news
-
Amgen announces plans to acquire Horizon for $27.8bn in biggest pharma deal for 2022
criteria’. Amgen will benefit from gaining several approved therapies as part of the deal, with Horizon’s pipeline of rare autoimmune and inflammatory disease drugs bolstering Amgen’s offering. ... Included in this is Horzion’s Tepezza, a
-
Sanofi’s Enjaymo receives EC approval for rare autoimmune haemolytic anaemia
Cold agglutinin disease affects around 12, 000 people in the US, Europe and Japan. ... Enjaymo is currently the only approved treatment for CAD, a rare type of autoimmune haemolytic anaemia where part of the body’s immune system mistakenly destroys
-
Alexion's Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial
Alexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) significantly reduced relapse risk in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) compared to an ... NMOSD is a rare
-
NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia
ITP is a rare autoimmune condition characterised by the destruction of platelets, which play an active role in blood clotting and healing. ... Tavlesse is the first new drug for treating chronic ITP in over a decade, addressing the unmet needs of
-
EC approves Alexion's Ultomiris as generalised myasthenia gravis treatment
The European Commission (EC) has approved Aexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) in Europe as an add-on to standard therapy for generalised myasthenia gravis (gMG). ... gMG is a rare, debilitating, chronic,
More from news
Approximately 1 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
The distressing impact of rare diseases
The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
